Icenticaftor (QBW251) is an oral enhancer of the cystic fibrosis transmembrane conductance regulator (CFTR) channel with an EC50 of 79 nM for F508del and 497 nM for G551D CFTR. Icenticaftor can be used in chronic obstructive pulmonary disease (COPD) and cystic fibrosis studies.
|Solubility (25°C)||DMSO ≥ 100 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Laura Carrasco-Hernndez, et al. Biomedicines. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
 Darren Le Grand, et al. J Med Chem. Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
 Shamsah Kazani, et al. J Cyst Fibros. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
 Steven M Rowe, et al. Int J Chron Obstruct Pulmon Dis. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial
|Related CFTR Products|
The CFTR potentiator CP-628006 enhances CFTR function in cystic fibrosis patient-derived air chamber cells by a mechanism of action different from that of existing potentiators such as ivacaftor.
NJH-2-057 is a conjugate of the deubiquitinase OTUB1 covalent ligand-linked lumacaftor, which stabilizes mutant CFTR proteins in cells.
GLPG2451 is an enhancer of cystic fibrosis transmembrane conductance regulator (CFTR) and effectively enhances cryo-rescued F508del CFTR with an EC50 of 11.1 nM.
FDL169 is a CFTR corrector that is designed to fix and restore the function of the defective CFTR protein.
Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.